1. Львов Д.К., Руководство по вирусологии: Вирусные инфекции человека и животных./ М- Издательство «МИА», 2013, -1200 с: ил. 2. Мельниченко А.В. Автореферат дисс. к.м.н. «Разработка и получение диагностических тест-систем к вирусу герпеса человека 6-го типа и их применение для изучения HHV-6-инфекции».2002г. 27с. 3. Salahuddin S.Z., Ablashi D.V., Markham P.D., et al. Isolation of a new virus, HBLV, in patients with limfoproliferative disordes. Science.1986, 234; 590-601 4. Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988;1:1065–1067. 5. Мелехина Е.В Автореферат дисс. д.м.н. «Инфекция, вызванная Human betaherpesvirus 6A/B у детей. Клинико-патогенетические аспекты, диагностика и терапия». 2019. 50 с. 6. Agut H, Bonnafous P, Gautheret-Dejean A. Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev. 2015;28:313–335. 7. Yamanishi K, Mori Y, Pellett PE. Human herpesviruses 6 and 7. In: Knipe DM, Howley PM, eds. Fields Virology. 6th ed. Philadelphia: Wolters Kluwer, Lippincott Williams & Wilkins; 2013:2013. 8. Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med. 2005;352:768–776. 9. Hall CB, Caserta MT, Schnabel KC, et al. Characteristics and acquisition of human herpesvirus (HHV) 7 infections in relation to infection with HHV-6. J Infect Dis. 2006;193:1063–1069. 10. Schirmer EC, Wyatt LS, Yamanishi K, et al. Differentiation between two distinct classes of viruses now classified as human herpesvirus 6. Proc Natl Acad Sci USA. 1991;88:5922–5926. 11. Мельниченко А.В., Алимбарова Л.М., Трегубова М.И., Мезенцева М.В., Баринский И.Ф., Львов Н.Д. Клинико-вирусологическая и иммунологическая характеристика больных с разными формами герпес-вирусных инфекций. Лечение и профилактика. 2017, т.: 7, №4 (24), 2017, с. 7-13. 12. Новосад Е.В. Автореферат дисс. к.м.н. «Инфекционный мононуклеоз, ассоциированный с вирусом герпеса 6-го типа 2010 г. 25с. 57 13. Komaroff A.L., M. Boeckh, E.Eliason. Summary of the 10th International Conference on Human Herpesviruses-6 and -7 (HHV-6A, -6B, and HHV-7)/ J med Virol - 2018 Apr;90(4):625-630. 14. Zerr D.M. Human herpesvirus 6: a clinical update // Herpes. 2006 May; 13 (1); 20-4 15. Yoshikawa T. Human herpesvirus-6 encephalitis.//Brain Nerve 2010, Aug;62 (8) 869-75 16. Инфекционные болезни: национальное руководство / под ред. Н.Д Ющука, Ю.Я. Венгерова–2-е изд., перераб. и доп.– М.: ГЭОТАР-Медиа, 2018. 1104 с 17. Исаков В. А., Архипова Е. И., Исаков Д. В. «Герпеcвирусные инфекции человека: руководство для врачей. — 2-е изд., перераб. и доп. / под ред. В. А. Исакова. — СПб.: СпецЛит, 2013. — 670 с. 18. Agut H., Bonnafous P., Gautheret-Dejean A. Human herpesviruses 6A, 6B and 7. //Microbiol. Spectr. 2016 Jan 4 (3) 19. E.Eliassen, E. Lum, J. Pritchetto. Human Herpesvirus 6 and Malignancy: A Review/ Front oncol 2018 Nov 13;8:512. 20. Новосад Е.В., Шамшева О.В., Львов Н.Д., Мельниченко А.В., Никитина А.А. и др. «Инфекционный мононуклеоз, ассоциированный с вирусом герпеса 6 типа», Матлы V конгресса педиатров-инфекционистов России, Москва,2006г.169. 21. Godet A.N., Soignon G., Koubi H. Presence of HHV-6 genome in spermatozoa in context of couples with low fertility; what type of infection?// Andrologia. 2015 Jun; 47(5); 531-535 22. Caserta MT, Hall CB, Schnabel K, et al. Human herpesvirus (HHV)-6 and HHV-7 infections in pregnant women. J Infect Dis. 2007;196:1296–1303. 23. Caserta MT, Hall CB, Canfield RL, et al. Early developmental outcomes of children with congenital HHV-6 infection. Pediatrics. 2014;134:1111–1118. 24. Hall CB, Caserta MT, Schnabel K, et al. Cоngenital infections with human herpes virus 6 (HHV-6) and human herpes virus 7 (HHV-7) . J. Paediatr. 2004; 145; 472-477 25. Hall CB, Caserta MT, Schnabel K, et al. Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics. 2008;122:513–520. 26. Pruksananonda P, Hall CB, Insel RA, et al. Primary human herpesvirus 6 infection in young children. N Engl J Med. 1992;326: 1445–1450. 27. Tanaka K, Kondo T, Torigoe S, et al. Human herpesvirus 7: another causal agent for roseola (exanthem subitum). J Pediatr. 1994;125:1–5. 58 28. Asano Y, Yoshikawa T, Suga S, et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics. 1994;93:104– 108. 29. Caserta MT, McDermott MP, Dewhurst S, et al. Human herpesvirus 6 (HHV6) DNA persistence and reactivation in healthy children. J Pediatr. 2004;145:478–484. 30. Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children: a prospective study of complications and reactivation. N Engl J Med. 1994;331:432–438. 31. Никольский М.А, Радыш М.В. Роль вирусов герпеса человека 6 и 7-го типов в возникновении фебрильных судорог у детей // Вопросы диагностики и педиатрии. 2012. Т. 4. № 4, с. 46–48. 32. Веселова Е.И., Мелехина Е.В., Чугунова О.Л., Любезнова И.Г. Клинические особенности течения острых форм инфекции, ассоциированной с вирусом герпеса 6-го типа у детей раннего возраста / Материалы XII Конгресса детских нфекционистов России «Актуальные вопросы инфекционной патологии и вакцинопрофилактики» М., 2013. С. 18. 33. Potenza L, Luppi M, Barozzi P, et al. HHV-6A in syncytial giant-cell hepatitis. N Engl J Med. 2008;359:593–602. 34. Мurakami K. A study of the relationship between initial febrile seizures and human herpes virus 6, 7 infections // No To Hattatsu. 2004; 36 (3): 248–252. 35. Eliassen E, C.C.Hemond, J.D Santoro. HHV-6-Associated Neurological Disease in Children: Epidemiologic, Clinical, Diagnostic, and Treatment Considerations / Pediatr Neurol 2020 Apr;105:10-20. 36. Sleuker A.K., T.L. Royer, T.Villabos. Human Herpesvirus 6 Positivity on the FilmArray Meningitis/Encephalitis Panel Needs Clinical Interpretation . Clin.Infect Dis.2019 june 18 . 69(1) 192-194 37. Ward K. N., Andrews N. J., Verity C. M. et al. Human herpesvirus-6 and 7 each cause significant neurological morbidity in Britain and Ireland // Arch. Dis. Child. 2005; 90 (6): 619–623. 38. Broccolo F., Ciccareso G., Oggioni M// The saliva quantitative PCR assay is inadequated to detect and monitor HHV-7 and 6 reactivation in patients with Pityriasis Rosea. J. Clin. Virol. 2014. 61(4), 615-6 39. Harberts E, Yao K, Wohler JE, et al. Human herpesvirus-6 entry into the central nervous system through the olfactory pathway. Proc Natl Acad Sci USA. 2011;108:13734–13739. 59 40. Suga S, Suzuki K, Ihira M, et al. Clinical characteristics of febrile convulsions during primary HHV-6 infection. Arch Dis Child. 2000;82:62–66. 41. Shinnar S, Hesdorffer DC, Nordli DR, et al. Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. FEBSTAT study team. Epilepsia. 2012;53:1481–1488. 42. Ongrádi J, Ablashi DV, Yoshikawa T, et al. Roseolovirusassociated encephalitis in immunocompetent and immunocompromised individuals. J Neurovirol. 2017;23:1–19. 43. Suga S, Yoshikawa T, Asano Y, et al. Clinical and virological analyses of 21 infants with exanthem subitum (roseola infantum) and central nervous system complications. Ann Neurol. 1993;33:597–603. 44. Ward KN, Andrews NJ, Verity CM, et al. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child. 2005;90:619– 623. 45. McCullers JA, Lakeman FD, Whitley RJ. Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis. 1995;21:571–576. 46. Shahani L. HHV-6 encephalitis presenting as status epilepticus in an immunocompetent patient. BMJ Case Rep. 2014;pii:bcr2014205880. 47. Isaacson E, Glaser CA, Forghani B, et al. Evidence of human herpesvirus 6 infection in 4 immunocompetent patients with encephalitis. Clin Infect Dis. 2005;40:890–893. 48. Reddy S, Eliassen E, Krueger GR, et al. Human herpesvirus 6-induced inflammatory cardiomyopathy in immunocompetent children. Ann Pediatr Cardiol. 2017;10:259–268. 49. Akashi K, Eizuru Y, Sumiyoshi Y, et al. Brief report: severe infectious mononucleosislike syndrome and primary human herpesvirus 6 infection in an adult. N Engl J Med. 1993;329:168–171. 50. Maric I, Bryant R, Abu-Asab M, et al. Human herpesvirus-6-associated acute lymphadenitis in immunocompetent adults. Mod Pathol. 2004;17:1427–1433. 51. Ongradi J., Ablashi D.V., Yoshikawa T. Roseolovirus-associated encephalitis in immunocompetent and immunocompromised individuals.//J.Neurovirol, 2017 Feb; 23(1); 1-19 52. Clark DA, Nacheva EP, Leong HN, et al. Transmission of integrated human herpesvirus 6 through stem cell transplantation: implications for laboratory diagnosis. J Infect Dis. 2006;193:912–916. 53. Boutolleau D, Fernandez C, André E, et al. Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients. J Infect Dis. 2003;187:179–186. 54. Plan T.L., Lautenschlager I., Rasonable R.R. HHV-6 in liver transplantation: a literature review// Liver Int. 2018 Feb; 38(2); 210-223 55. Santoro J.D, Hemond C.C. Human herpesvirus 6 associated post-transplant acute limbic encephalitis: Clinical observations of biomarkers for risk of seizure in a pediatric population Transpl . Infect Dis . 2019 Feb;21(1):e13003 56. Lautenschlager I., Rasonable R.R. Human herpesvirus 6-infections in kidney, liver, lung and heart transplantation: review//Transpl. Int. 2012 May: 25(5); 943-502 57. Epstein D.J., Tan S.K., Deresinski S. HHV-6 and septic shock: Tenuous proof of causation//Am.J.Transplant. 2019 Jan 19(1); 303 58. Wescheke D.P, W.M. Leisenring, R.L. Lawler. Inflammatory Cytokine Profile in Individuals with Inherited Chromosomally Integrated Human Herpesvirus 6 /Biol Blood Marrou Transplant 2020 Feb;26(2):254-261Dockrell DH, Paya CV. Human herpesvirus-6 and -7 in transplantation. Rev Med Virol. 2001;11:23–36. 59. Härmä M, Höckerstedt K, Lautenschlager I. Human herpesvirus-6 and acute liver failure. Transplantation. 2003;76:536–539. 60. Sashihara J, Tanaka-Taya K, Tanaka S, et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood. 2002;100:2005–2011. 61. Illiaquer M, Malard F, Guillaume T, et al. Long-lasting HHV-6 reactivation in long-term adult survivors after double umbilical cord blood allogeneic stem cell transplantation. J Infect Dis. 2014;210:567–570. 62. Razonable RR, Fanning C, Brown RA, et al. Selective reactivation of human herpesvirus 6 variant occurs in critically ill immunocompetent hosts. J Infect Dis. 2002;185:110–113. 63. Chang FY, Singh N, Gayowski T, et al. Fever in liver transplant recipients: changing spectrum of etiologic agents. Clin Infect Dis. 1998;26:59–65. 64. Zerr DM, Corey L, Kim HW, et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:932– 940. 65. Ljungman P, Wang FZ, Clark DA, et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol. 2000;111:774–781. 66. Isomura H, Yamada M, Yoshida M, et al. Suppressive effects of human herpesvirus 6 on in vitro colony formation of hematopoietic progenitor cells. J Med Virol. 1997;52:406– 412. 61 67. Yoshikawa T, Asano Y, Ihira M, et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. J Infect Dis. 2002;185:847–853. 68. Aoki J, Numata A, Yamamoto E, et al. Impact of human herpesvirus-6 reactivation on outcomes of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:2017–2022. 69. Ogata M, Satou T, Kadota J, et al. Human herpesvirus 6 (HHV-6) reactivation and HHV6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study. Clin Infect Dis. 2013;57:671–681. 70. Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. Bone Marrow Transplant. 2015;50:1030–1036. 71. Scheurer ME, Pritchett JC, Amirian ES, et al. HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis. Bone Marrow Transplant. 2013;48:574–580. 72. Ogata M, Oshima K, Ikebe T, et al. Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:1563–1570. 73. Miyashita N, Endo T, Onozawa M, et al. Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2017;19:doi:10.1111/tid.12682. 74. Ogata M, Satou T, Kawano R, et al. Correlations of HHV-6 viral load and plasma IL-6 concentration with HHV-6 encephalitis in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2010;45:129–136. 75. Zerr DM. Human herpesvirus 6 and central nervous system disease in hematopoietic cell transplantation. J Clin Virol. 2006;37(suppl 1):S52–S56. 76. Fotheringham J, Akhyani N, Vortmeyer A, et al. Detection of active human herpesvirus6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis. 2007;195:450–454. 77. Cuomo L, Trivedi P, Cardillo MR, et al. Human herpesvirus 6 infection in neoplastic and normal brain tissue. J Med Virol. 2001;63:45–51. 78. Wainwright MS, Martin PL, Morse RP, et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol. 2001;50:612–619. 79. Seeley WW. Post-transplant acute limbic encephalitis. Neurology. 2007;69:156–165. 62 80. Sakai R, Kanamori H, Motohashi K, et al. Long-term outcome of human herpesvirus-6 encephalitis after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1389–1394. 81. Zerr DM, Fann JR, Breiger D, et al. HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood. 2011;117:5243–5249. 82. Hill JA, Boeckh M, Leisenring WM, et al. Human herpesvirus 6B reactivation and delirium are frequent and associated events after cord blood transplantation. Bone Marrow Transplant. 2015;50:1348–1351. 83. Ueki T, Hoshi K, Hiroshima Y, et al. Analysis of five cases of human herpesvirus-6 myelitis among 121 cord blood transplantations. Int J Hematol. 2018;107:363–372. 84. Cone RW, Hackman RC, Huang ML, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med. 1993;329:156–161. 85. Fernández-Ruiz M, Kumar D, Husain S, et al. Utility of a monitoring strategy for human herpesviruses 6 and 7 viremia after liver transplantation: a randomized clinical trial. Transplantation. 2015;99:106–113. 86. Kawano Y., Miyazaki T., Watanabe T. et al. HLA-mismatched CD34-selected stem cell transplant complicated by HHV-6 reactivation in the central nervous system // Bone Marrow Transplant. 2000, 25 (7): 787–790. 87. Leong HN, Tuke PW, Tedder RS, et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol. 2007;79:45–51. 88. Clark DA. Clinical and laboratory features of human herpesvirus 6 chromosomal integration. Clin Microbiol Infect. 2016;22:333–339. 89. Sedlak RH, Hill JA, Nguyen T, et al. Detection of human herpesvirus 6B (HHV-6B) reactivation in hematopoietic cell transplant recipients with inherited chromosomally integrated HHV-6A by droplet digital PCR. J Clin Microbiol. 2016;54:1223–1227. 90. Gravel A, Dubuc I, Morissette G, et al. Inherited chromosomally integrated human herpesvirus 6 as a predisposing risk factor for the development of angina pectoris. Proc Natl Acad Sci USA. 2015;112:8058–8063. 91. Hill JA, Magaret AS, Hall-Sedlak R, et al. Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV6. Blood. 2017;130:1062–1069. 63 92. Lee SO, Brown RA, Razonable RR. Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients. Transplantation. 2011;92:224–229. 93. Wescheke D.P, W.M. Leisenring, R.L. Lawler. Inflammatory Cytokine Profile in Individuals with Inherited Chromosomally Integrated Human Herpesvirus 6 /Biol Blood Marrou Transplant 2020 Feb;26(2):254-261. 94. Cermelli C, Berti R, Soldan SS, et al. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis. 2003;187:1377– 1387. 95. Goodman AD, Mock DJ, Powers JM, et al. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J Infect Dis. 2003;187:1365–1376. 96. Leibovitch EC, Jacobson S. Evidence linking HHV-6 with multiple sclerosis: an update. Curr Opin Virol. 2014;9:127–133. 97. Fotheringham J, Donati D, Akhyani N, et al. Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med. 2007;4:e180. 98. Kawamura Y, Nakayama A, Kato T, et al. Pathogenic role of human herpesvirus 6B infection in mesial temporal lobe epilepsy. J Infect Dis. 2015;212:1014–1021. 99. Leibovitch EC, Jacobson S. Human herpesvirus 6 as a viral trigger in mesial temporal lobe epilepsy. J Infect Dis. 2015;212:1011–1013. 100.Casell Е, I.Soffritti, M.D Accolti. HHV-6A Infection and Systemic Sclerosis: Clues of a Possible Association /Microorganisms/ 2019. Dec 24, 8(1):. 39 101.Jeong H.H, Z. Liu. Area HHV-6A and HHV-7 Really More Abundant in Alzheimer's Disease? Neuron . 2019 Dec 18;104(6):1034-1035 102. E.Eliassen, E. Lum, J. Pritchetto. Human Herpesvirus 6 and Malignancy: A Review/ Front oncol 2018 Nov 13;8:512 103.Ashshi A. M., Klapper P. E., Cooper R. J. Detection of human cytomegalovirus, human herpesvirus type 6 and human herpesvirus type 7 in urine specimens by multiplex PCR // J Infect. 2003; 47 (1): 59–64 104.Zheng Y, Zhao Y, Wang Y, Jun Rao. A multiplex real-time PCR quantitation of human herpesvirus 6, 7, 8 ; application in blood transfusions. Virology J 2021. 10.1186/sl12985- 021-01510-6, 18, 1 105.Исаков В.А., Исаков Д.В. Иммуномодуляторы в терапии и профилактике герпесвирусных инфекций. Клиническая медицина. 2015; 93(4): С. 16 – 24. 64 106.Сологуб Т.В., Романцов М.Г., Рыбалкина Т.С., Рыбалкин С.Б., Смагина А.Н., Исаков В.А., Коваленко А.Л. Модифицированная терапия герпетической инфекции. Клиническая медицина. 2011; 89 (3): С. 54 – 57. 107.Каражас Н.В., Малышев Н.А., Рыбалкина Т.Н. и др. Современные аспекты герпесвирусной инфекции. Эпидемиология, клиника, диагностика, лечение и профилактика: методические рекомендации. – М.: Спецкнига, 2012, 128 с. 108.Ершов Ф.И. Антивирусные препараты. М.: Гэотар-Медиа, 2006: 312 109. Cardamakis E., Relakis K., Kotoulas I. G. et al. Treatment of recurrent genital herpes with interferon alpha-2 alpha // Gynecol. Obstet. Invest. 1998, 46 (1): 54–57 110.Калугина М. Ю., Каражас Н. В., Рыбалкина Т. Н., Бошьян Р. Е., Ермакова Т М.,Тебеньков А. В. Актуальность диагностики инфекции, вызванной вирусом герпеса человека 6-го типа // Детские инфекции. 2012. № 1. С. 60–63 111. Becerra A.,Gibson L., Stern L.J. Immune response to HHV-6 and implications for immunotherapy.//Curr Opin Virol 2014, 9 , 154-61 112.Wintergerst U., Belohradsky B. H. Acyclovir monotherapy versus acyclovir plus betainterferon in focal viral encephalitis in children // Infection. 1992, 20 (4): 207–212 113.Wintergerst U., Kugler K., Harms F. et al. Therapy of focal viral encephalitis in children with aciclovir and recombinant beta-interferon — results of a placebo-controlled multicenter study // Eur. J. Med. Res. 2005, 10 (12): 527–531 114. Karam C., Revuelta M., Macgowan D. Human herpesvirus 6 meningoradiculitis treated with intravenous immunoglobulin and valganciclovir // J. Neurovirol. 2009, 15 (1): 108 115. Agut H. Acute human herpesvirus (HHV-6) infections: when and how to treat? //Pathol. Biol. (Paris) 2011, Apr 59(2); 108-12 116. Prichard M.N., Whitley R.J., // The development of new therapies for human herpes virus 6// Curr Opin Virol. 2014, 9, 148-53 117. Деленян Н.В., Ариненко Р.Ю., Мешкова Е.Н. Виферон. Комплексный противовирусный и иммуномодулирующий препарат для детей и взрослых. Руководство для врачей. М.: ИНКО-ТНК, 2002: 52 с 118. Wintergerst U., Kugler K., Harms F. et al. Therapy of focal viral encephalitis in children with aciclovir and recombinant beta-interferon — results of a placebo-controlled multicenter study // Eur. J. Med. Res. 2005, 10 (12): 527–531. 119. Williams-Aziz SL, Hartline CB, Harden EA. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother. 2005;49: 3724–3733. 120. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47:303–327. 121. Manichanh C, Olivier-Aubron C, Lagarde JP, et al. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol. 2001;82:2767–2776. 122. Tokimasa S, Hara J, Osugi Y, et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:595–598. 123. Rapaport D, Engelhard D, Tagger G, et al. Antiviral prophylaxis may prevent human - herpesvirus-6 reactivation in bone marrow transplant recipients.Transpl Infect Dis2002;4:10-16. 124. Cheng FW, Lee V, Leung WK, et al. HHV-6 encephalitis in pediatric unrelated umbilical cord transplantation: a role for ganciclovir prophylaxis? Pediatr Transplant. 2010;14:483–487. 125. Ishiyama K, Katagiri T, Ohata K, et al. Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stemcelltransplantation.Transpl Infect Dis.2012;14:33–39. 126. Prichard MN, Williams JD, Komazin-Meredith G, et al. Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses. Antimicrob Agents Chemother. 2013;57:3518–3527. 127. Prichard MN, Frederick SL, Daily S, et al.Benzimidazole analogs inhibit human herpesvirus 6. Antimicrob Agents Chemother. 2011;55:2442–2445. 128. Боковой АГ, Егоров АИ. Герпесвирусные инфекции у детей и родителей: учебное пособие для врачей педиатров, инфекционистов, иммунологов. Хабаровск: Полиграф-Партнер; 2016. 129.Pantry SN, Medveczky PG. Latency, Integration, and Reactivation of Human Herpesvirus-6. Viruses. 2017;9(7):194-206. 130.Agut H, Bonnafous P, Gautheret-Dejean A. Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev. 2015 Apr;28(2):313-35. DOI: 10.1128/CMR.00122-14 131.Human Herpesviruses HHV-6A, HHV-6B, and HHV-7. Diagnosis and Clinical Management / Edited by Flamand L. Amsterdam: Elsevier; 2014 66 132.De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev. 2005 Jan;18(1 ):217-45. DOI: 10.1128/CMR. 18.1.217-245.2005 133.Agut H, Bonnafous P, Gautheret-Dejean A. Update on infections with human herpesviruses 6A, 6B, and 7. Med Mai Infect. 2017 Mar;47(2):83-91. DOI: 10.1016/j. medmal.2016.09.004 134.Gallois-Montbrun S, Schneider B, Chen Y, Giacomoni-Fernandes V, Mulard L, Morera S, et al. Improving nucleoside diphosphate kinase for antiviral nucleotide analogs activation. J Biol Chem. 2002 Oct 18;277(42):39953-9. DOI: 10.1074/jbc. M206360200 135.Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 -Aug;10 Suppl 3:S490-4. DOI: 10.1093/clinids/10. supplement3.s490 136.Ogata M, Phan TL, Fukuda T. Antiviral therapy for the treatment of HHV-6-associated syndromes after transplant. Am J Transplant. 2019 Jan;19(1 ):306-307. DOI: 10.1111/ajt.15069 137.Bonnafous P, Naesens L, Petrella S, Gautheret-Dejean A, Boutolleau D, Sougakoff W, et al. Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet. Antivir Ther. 2007;12(6):877-88. 138.Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis. 2004 Aug 1;190(3):499-503. DOI: 10.1086/421912 139.Мелёхина Е.В, Музыка А.Д, Понежева Ж.Б. Оценка эффективности противовирусной терапии активной инфекции, вызванной ВГЧ-6А/В у детей 4 лет и старше. / Вопросы практической педиатрии 2020, том 15, № 2, стр. 32-40 140.Вершинина EH, Иванова BB, Говорова ЛВ. Терапевтическая коррекция иммунных расстройств при респираторных заболеваниях у детей с герпесвирусным инфицированием. Информационно-методическое письмо для врачей СПб., 2007. 141.Краснов ВВ, Кулова АА, Воробьева ВВ, Бушуев МГ, Обрядина АП, Астраханцева ИВ. Эффективность применения циклоферона у часто болеющих детей, имеющих маркеры активности герпесвирусных инфекций. Вестник Санкт-Петербургской государственной академии им. И.И.Мечникова. 2009; 1:148-53. 142. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. 2019 г, утв.пленумом правления национального научного общества инфекционистов 13.09.2019. - Эпидемиология и инфекционные болезни 2019 год №4 Приложение, 87 с